GSK, Cold Spring Harbor Laboratory to develop obesity, Type 2 diabetes treatment

By Zachary Brennan

- Last updated on GMT

GSK, Cold Spring Harbor Laboratory to develop obesity, Type 2 diabetes treatment

Related tags Obesity Diabetes mellitus type 2

Cold Spring Harbor Laboratory (CSHL) will collaborate with GlaxoSmithKline to develop treatments for obesity and Type 2 diabetes. 

The goal of the multi-year collaboration is to identify potent, selective, orally bioavailable small molecules that inhibit PTP1B activity in vivo following stimulation by insulin and leptin, which would be expected to overcome insulin and leptin resistance that is encountered in diabetes and obesity. Scientists at CSHL and GSK will pursue the drug development based on a novel approach to regulate the enzymatic activity of the phosphatase PTP1B.

A spokesman for CSHL told the research collaboration “is expected to last about three years​,” though it “could be longer if a successful therapy candidate is identified​.” And as far as pay out, if a candidate identified in the collaboration becomes a product, CSHL would receive a royalty on the sales of that product, he added.
The work at CSHL will be led by Professor Nicholas Tonks, who discovered PTP1B and is an expert on the protein tyrosine phosphatase (PTP) family of enzymes and their roles in human diseases.

At GSK, we believe that combining the in-depth target and disease knowledge  of renowned academic groups with our drug-discovery expertise and capabilities can foster innovation and speed up the discovery and development of new medicines​,” said Carolyn Buser, global head of The Discovery Partnership with Academia program (DPAc) at GSK.  “We are excited to expand our partnerships in North America and look forward to working closely with Dr. Tonks, whose deep understanding of protein tyrosine phosphatase biology will complement our own work in this field​.” 

This collaboration would be one of 13 DPAc collaborations that GSK has in place at academic research institutions in North America and Europe.

GSK and CSHL also will provide project co-leadership across different sets of expertise to facilitate the development of novel therapeutics. 

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more